Skip to content
Awesome – Lifestyle
Author:
IDEAYA Biosciences, Inc.
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE034, a Potential First-In-Class B7H3/PTK7 Bispecific TOP1 ADC
March 4, 2026
←
Previous Page
1
2
3